

# Resource Summary Report

Generated by [dkNET](#) on Sep 6, 2026

## CD14-VioBlue, human

RRID:AB\_2660173

Type: Antibody

---

### Proper Citation

Miltenyi Biotec Cat# 130-098-058, RRID:AB\_2660173

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2660173](http://antibodyregistry.org/AB_2660173)

**Proper Citation:** Miltenyi Biotec Cat# 130-098-058, RRID:AB\_2660173

**Target Antigen:** CD14

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Discontinued: 6-2018; Target Distribution B cells, dendritic cells, epithelial cells, granulocytes, Langerhans cells, liver, macrophages, monocytes, osteoclasts, plasma cells; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-714. (RRID:AB\_2726255).

**Antibody Name:** CD14-VioBlue, human

**Description:** This monoclonal targets CD14

**Target Organism:** other, non-human primate, human

**Clone ID:** T??K4

**Antibody ID:** AB\_2660173

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-098-058

**Record Creation Time:** 20231110T034400+0000

**Record Last Update:** 20260829T205423+0000

---

## Ratings and Alerts

No rating or validation information has been found for CD14-VioBlue, human.

**Warning:** Discontinued: 2021

Discontinued: 6-2018; Target Distribution B cells, dendritic cells, epithelial cells, granulocytes, Langerhans cells, liver, macrophages, monocytes, osteoclasts, plasma cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-714. (RRID:AB\_2726255).

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Mulfaul K, et al. (2020) Toll-like Receptor 2 Facilitates Oxidative Damage-Induced Retinal Degeneration. Cell reports, 30(7), 2209.